Results for this period
Third quarter1 July 2025 to 31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The API sales business posted higher revenue and profit due to factors including greater market penetration of products launched in recent years and increased transaction volumes accompanying the expansion of generic drugs' volume share. In the pharmaceutical manufacturing and sales business, sales of the mainstay tablet products declined due to factors including competitor entry, while sales of prefilled syringe products and vial products for anticancer drugs remained solid.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 July 2025 to 31 March 2026 |
| Net Sales | ¥18,334 million (YoY +4.0%) |
| Operating profit | ¥4,580 million (YoY +4.5%) |
| Ordinary income | ¥4,551 million (YoY +3.0%) |
| Profit attributable to owners of the parent | ¥3,052 million (YoY +3.1%) |
| Net income per share | ¥72.47 |
| Equity ratio | End of the current fiscal period 80.2 / End of previous period 77.9 |
| Total assets | ¥38,039 million |
| Net assets | ¥30,494 million |
| Full-year earnings forecast | Net Sales ¥25,700 million (YoY +10.4%) / Operating profit ¥5,430 million (YoY +1.4%) / Ordinary income ¥5,430 million (YoY +1.0%) / Net income ¥3,640 million (YoY +0.1%) |
| Revision to Earnings Forecast | Net Sales 25,700 / Operating profit 5,430 / Ordinary income 5,430 / Net income 3,640 → No change（No） |
| Annual Dividend Forecast | ¥16 → ¥18（+12.5%） |
| Segment revenue | API sales business ¥12,248 million (YoY +4.4%), Pharmaceutical manufacturing and marketing business ¥7,024 million (YoY +2.1%) |
| Segment profit | API sales business ¥2,588 million (YoY +8.3%), Pharmaceutical manufacturing and marketing business ¥1,931 million (YoY -0.1%) |
| Depreciation and amortization | ¥452,030 thousand |
| Impairment loss | Amount No applicable matters / Subject assets No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥3,552 thousand / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 42,119,980 shares |
| Treasury Shares at Period-End | 1,476 shares |
| Factors Behind Changes in Business Performance | The API sales business posted higher revenue and profit due to factors including greater market penetration of products launched in recent years and increased transaction volumes accompanying the expansion of generic drugs' volume share. In the pharmaceutical manufacturing and sales business, sales of the mainstay tablet products declined due to factors including competitor entry, while sales of prefilled syringe products and vial products for anticancer drugs remained solid. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The active pharmaceutical ingredients (API) sales business posted higher revenue and profit due to factors including greater market penetration of products launched in recent years and increased transaction volumes accompanying the expansion of generic drugs' volume share. In the pharmaceutical manufacturing and sales business, sales of the mainstay tablet products declined following the entry of competitors, while prefilled syringe products and vial products for anticancer drugs remained solid.